Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 135
Filter
3.
J Dairy Sci ; 95(12): 7051-65, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23040027

ABSTRACT

The objective of this study was to evaluate the effect of supplementation with oral Ca boluses after calving on early-lactation health and milk yield. Cows in their second lactation or greater (n=927) from 2 large dairies in Wisconsin were enrolled during the summer of 2010. Both herds were fed supplemental anions during the prefresh period and less than 1% of fresh cows were treated for clinical milk fever. Cows were scored before calving for lameness and body condition, and then randomly assigned to either a control group or an oral Ca bolus-supplemented group. Control cows received no oral Ca boluses around calving. Cows in the oral Ca bolus group received 2 oral Ca boluses (Bovikalc, Boehringer Ingelheim, St. Joseph, MO), one bolus 0 to 2h after calving and the second 8 to 35 h after calving. The oral Ca bolus administration schedule allowed fresh cows to be restrained in headlocks only once daily. Whole-blood samples were collected immediately before the second oral Ca bolus was given and were analyzed for ionized Ca (Ca(2+)) concentration. Early-lactation health events were recorded and summed for each cow. Only 6 cases (0.6% of calvings) of clinical milk fever occurred during the trial, and only 14% of cows tested were hypocalcemic (Ca(2+) less than 1.0 mmol/L) at 8 to 35 h after calving. Mean Ca(2+) concentrations were not different between the control and oral Ca bolus-supplemented groups. Blood samples from the cows given oral Ca boluses were collected an average of 20.6 h after administration of the first bolus. Subpopulations of cows with significant responses to oral Ca bolus supplementation were identified based on significant interactions between oral Ca bolus supplementation and covariates in mixed multiple regression models. Lame cows supplemented with oral Ca boluses averaged 0.34 fewer health events in the first 30 d in milk compared with lame cows that were not supplemented with oral Ca boluses. Cows with a higher previous lactation mature-equivalent milk production (greater than 105% of herd rank) and supplemented with oral Ca boluses produced 2.9 kg more milk at their first test after calving compared with cows with higher previous lactation milk yields that were not supplemented. Results of this study indicate that lame cows and higher producing cows responded favorably to supplementation with oral Ca boluses. Supplementing targeted subpopulations of cows with oral Ca boluses was beneficial even for dairies with a very low incidence of hypocalcemia.


Subject(s)
Calcium/pharmacology , Cattle/physiology , Lactation/drug effects , Administration, Oral , Animals , Calcium/administration & dosage , Diet/veterinary , Dietary Supplements , Female , Lactation/physiology , Milk/metabolism
4.
Oral Dis ; 18(3): 255-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22050355

ABSTRACT

OBJECTIVES: (i) To determine whether salivary cortisol and electrolyte levels differ between patients with Sjogren's syndrome (SjS) and healthy individuals. (ii) To assess correlations between whole-saliva cortisol and some clinical manifestations in patients with SjS. METHODS: A total of 24 healthy women (mean age 49.3±9.8) served as controls (C) vis-à-vis 17 patients with SjS (mean age 55.5±15.7). Salivary cortisol concentration was determined, and sialochemistry analysis was performed. RESULTS: Significantly lower saliva flow rates and higher salivary chloride (Cl(-) ), potassium (K(+) ), and Ca(2+) levels were found in the SjS group. No significant differences or correlations were found in other parameters, including sodium (Na(+) ), magnesium (Mg(2+) ), phosphate ((-) ), urea (U), and salivary cortisol levels. CONCLUSION: Increased whole-salivary output of Cl(-) and K(+) in SjS may reflect release from apoptotic rests of acinar cells after secondary necrosis. Normal levels of salivary Na(+) , Mg(2+) , and (-) argue against concentration effect, deranged tubular function or cortisol (mineralocorticosteroid) effect as the cause for these findings. Increased salivary Ca(2+) levels probably reflect leakage of plasma Ca(2+) through the injured oral mucosa in SjS. In spite of disease-associated stress, salivary cortisol, a stress biomarker, was not increased, suggesting insufficient hypothalamus-pituitary-adrenal (HPA) axis response and/or local consumption of cortisol by lymphocyte infiltrates.


Subject(s)
Hydrocortisone/analysis , Saliva/chemistry , Sjogren's Syndrome/metabolism , Acinar Cells/metabolism , Apoptosis/physiology , Calcium/analysis , Case-Control Studies , Chlorides/analysis , Electrolytes/analysis , Female , Humans , Magnesium/analysis , Middle Aged , Phosphates/analysis , Potassium/analysis , Saliva/metabolism , Secretory Rate , Sodium/analysis , Urea/analysis
5.
Eur Respir J ; 34(1): 95-102, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19164344

ABSTRACT

Surfactant protein (SP)-D is a lung-derived protein that has been proposed as a biomarker for inflammatory lung disease. Serum SP-D was evaluated as a biomarker for components of chronic obstructive pulmonary disease (COPD) in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort and its response assessed to the administration of the anti-inflammatory agent prednisolone. The median level of serum SP-D was significantly elevated in 1,888 individuals with COPD compared to 296 current and former smokers without airflow obstruction (121.1 and 114.3 ng x mL(-1), respectively; p = 0.021) and 201 nonsmokers (82.2 ng x ml(-1); p<0.001). There was no correlation with the severity of COPD. Individuals with COPD who had a serum SP-D concentration that was greater than the 95th percentile of nonsmokers (175.4 ng x mL(-1)) showed an increased risk of exacerbations over the following 12 months (adjusted OR 1.30; 95% CI 1.03-1.63). Treatment with 20 mg x day(-1) prednisolone for 4 weeks resulted in a fall in serum SP-D levels (126.0 to 82.1 ng x mL(-1); p<0.001) but no significant change in post-bronchodilator forced expiratory volume in 1 s. Serum SP-D concentration is raised in smokers and may be useful in identifying individuals who are at increased risk of exacerbations of COPD. It may represent an intermediate measure for the development of novel anti-inflammatory agents.


Subject(s)
Biomarkers/metabolism , Gene Expression Regulation , Lung Diseases/blood , Lung Diseases/immunology , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Surfactant-Associated Protein D/blood , Adult , Aged , Cohort Studies , Female , Humans , Inflammation , Male , Middle Aged , Risk , Smoking
6.
Thorax ; 63(12): 1058-63, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18757456

ABSTRACT

BACKGROUND: Circulating levels of Clara cell secretory protein-16 (CC-16) have been linked to Clara cell toxicity. It has therefore been suggested that this protein may be a useful marker of chronic obstructive pulmonary disease (COPD). METHODS: Serum CC-16 levels were measured in 2083 individuals aged 40-75 years with COPD and a smoking history of >or=10 pack-years, 332 controls with a smoking history of >or=10 pack-years and normal lung function and 237 non-smoking controls. RESULTS: Serum CC-16 had a coefficient of repeatability of 2.90 over 3 months in a pilot study of 267 individuals. The median serum CC-16 level was significantly reduced in a replication group of 1888 current and former smokers with COPD compared with 296 current and former smokers without airflow obstruction (4.9 and 5.6 ng/ml, respectively; p<0.001) and 201 non-smokers (6.4 ng/ml; p<0.001). Serum levels of CC-16 were lower in current than in former smokers with GOLD stage II and III COPD but were not different in individuals with stage IV disease. Former, but not current smokers, with COPD had lower serum CC-16 levels with increasing severity of COPD (GOLD II vs GOLD IV COPD: 5.5 and 5.0 ng/ml, p = 0.006; r = 0.11 with forced expiratory volume in 1 s, p<0.001) and had significantly higher levels if they also had reversible airflow obstruction (p = 0.034). Serum CC-16 was affected by gender and age (r = 0.35; p<0.001) in subjects with COPD but not by body mass index or the presence of either chronic bronchitis or emphysema. CONCLUSIONS: Serum CC-16 levels are reduced in individuals with COPD and there is a weak correlation with disease severity in former smokers.


Subject(s)
Pulmonary Disease, Chronic Obstructive/diagnosis , Uteroglobin/blood , Adult , Aged , Biomarkers/blood , Biomarkers/metabolism , Cohort Studies , Female , Humans , Longitudinal Studies , Male , Middle Aged , Pilot Projects , Sensitivity and Specificity , Smoking/adverse effects , Smoking/blood , Uteroglobin/metabolism
7.
J Pharm Biomed Anal ; 38(4): 703-8, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-15967298

ABSTRACT

A quantitative, one-step, competitive electrochemiluminescence (ECL)-based immunoassay for the determination of a fully human, anti-TNFalpha monoclonal antibody in human serum has been developed. A biotinylated, mouse anti-variable region-specific antibody and a ruthenium-labeled anti-TNFalpha antibody were the only specific reagents needed to develop the assay. A single incubation step of 2 h followed by ECL detection was used. The assay was capable of measuring the analyte in neat serum over approximately a 1600-fold range with higher concentrations measured following a single dilution. Assay accuracy, precision, and reproducibility were suitable to support pharmacokinetic studies of the analyte. This competitive assay format offers an alternative approach to the development of immunoassays for the measurement of macromolecules in complex matrices to support preclinical and clinical studies.


Subject(s)
Antibodies, Monoclonal/blood , Immunoassay/methods , Tumor Necrosis Factor-alpha/immunology , Animals , Antibody Specificity , Arthritis, Rheumatoid/blood , Biotin , Humans , Indicators and Reagents , Luminescent Measurements , Mice , Reference Standards , Reproducibility of Results , Ruthenium
8.
Int J Gynecol Cancer ; 13(2): 111-9, 2003.
Article in English | MEDLINE | ID: mdl-12657109

ABSTRACT

The aim of this study was to identify the psychosocial needs of patients after treatment for gynecological malignancies and their views concerning the role physicians should take in meeting those needs. Self-administered questionnaires were answered by 95 patients at least 6 months after completion of therapy. Topic areas included emotional needs, spiritual concerns, patient-family communication, patient participation in decision making, and advance directives. In addition, all participants completed the Functional Assessment of Cancer Therapy (FACT-G, version 4) quality of life questionnaire. Fifty-seven percent of respondents stated that they had needed help dealing with emotional problems, and 73% wanted the physician to ask whether help is needed. The most common emotional concerns were feeling nervous (40% of subjects), being worried (34%), fear (25%), needing someone to talk to (24%), sadness (21%), and loss of control (17%). Fifty-nine percent stated that physicians should ask whether help is needed in discussing spiritual matters. Sixty-one percent stated that physicians should ask patients whether they want help starting conversations with their families about difficult-to-raise topics such as the possibility of dying. Forty-six of 86 respondents (53%) stated that discussions about advance directives such as living wills should take place soon after the cancer diagnosis has been established. Most patients surveyed want physicians to take an active role in dealing with psychosocial needs.


Subject(s)
Genital Neoplasms, Female/psychology , Genital Neoplasms, Female/therapy , Palliative Care , Physician's Role , Physician-Patient Relations , Social Support , Adult , Aged , Aged, 80 and over , Communication , Female , Humans , Middle Aged , North Carolina , Surveys and Questionnaires
9.
Int J Gynecol Cancer ; 12(4): 389-93, 2002.
Article in English | MEDLINE | ID: mdl-12144688

ABSTRACT

The objective of this study was to determine if breast cancer risk assessment following the Gail model should be incorporated into a gynecologic oncology clinic. The Gail model was used to assess the risk of breast cancer in 329 patients with preinvasive lower genital tract disease (Pre, n = 86), invasive vulvar and cervical (Cx, n = 102), uterine (Ut, n = 87), and ovarian cancer (Ov, n = 54) seen in an inner city gynecologic oncology office. T-test, chi square test, and Pearson and Spearman correlation coefficients were used for statistical evaluation. A P-value of less than 0.05 was regarded significant. An estimated 5-year risk of breast cancer of 1.67 or more was noted in 9% of the Pre patients, 5% of Cx patients, 21% of the Ut patients, and 9% of the Ov patients. The difference between Cx and Ut patients was significant. The average 5-year risk was calculated at 0.77 for Pre patients, 0.77 for Cx patients, 1.18 for Ut patients, and 1.11 for Ov patients. These differences were significant, but mirror the age distribution. The average age was 43.6 for Pre patients, 52.2 years for Cx, 61.5 years for Ut, and 58.5 years for Ov patients; these differences were significant. When calculations were corrected for the mean age (53 years), there were no significant differences between groups regarding the average risk: Pre: 1.04, Cx: 0.81, Ut: 0.96, Ov: 0.97. Only eight patients (2.4%), six of them in the Pre and Cx group, would be expected to derive significant benefit from tamoxifen therapy. We conclude that elevated 5-year breast cancer risk to 1.67% or higher is noted in about 11% of patients seen in a gynecologic oncology office, mainly related to age and family history. Risk assessment and regular screening should be part of any follow-up exam.


Subject(s)
Breast Neoplasms/etiology , Breast Neoplasms/prevention & control , Mass Screening/methods , Risk Assessment , Women's Health Services , Adult , Aged , Female , Genital Neoplasms, Female/prevention & control , Gynecology , Humans , Medical Oncology , Middle Aged , North Carolina , Urban Health Services
10.
J Drug Educ ; 32(1): 41-52, 2002.
Article in English | MEDLINE | ID: mdl-12096556

ABSTRACT

A collegiate athlete population was surveyed for alcohol abuse as well as self-reported depression, anxiety, and other psychiatric symptoms. This study revealed that in a group of 262 athletes there were 21 percent who reported high alcohol use and problems associated with its use. Significant correlations were found between reported alcohol abuse and self-reported symptoms of depression and general psychiatric symptoms. Subjects with positive depression and psychiatric symptom ratings in the "severe" range had a significantly higher rate of alcohol abuse than subjects who had low depression and low or mild symptom ratings. Conversely, subjects reporting higher rates of alcohol misuse had more psychiatric symptoms. These findings suggest a possible causal link between psychopathology and serious alcohol abuse among college athletes. They also point to the need for routine depression and anxiety screening in college students who are typically beginning a significant exposure to alcohol.


Subject(s)
Alcohol Drinking/epidemiology , Mental Disorders/epidemiology , Self Medication , Sports , Students/psychology , Adult , Depression , Female , Humans , Logistic Models , Male , Surveys and Questionnaires , Universities
11.
Pediatr Radiol ; 31(5): 358-64, 2001 May.
Article in English | MEDLINE | ID: mdl-11373927

ABSTRACT

BACKGROUND: Although the pathologic features and imaging appearance of childhood primary ovarian neoplasms have been well described, little information is available about the malignancies that may secondarily involve the ovary. OBJECTIVE: To determine the relationship between the imaging features and the histopathology of secondary ovarian neoplasms in children treated at our institution. MATERIALS AND METHODS: We searched our institutional database for codes indicating metastatic ovarian disease. Of the 35 patients with such codes, 18 had pathologically proven secondary ovarian disease. From their medical records we recorded demographic data, presenting symptoms, and evidence of endocrine dysfunction. We reviewed the pre-oophorectomy imaging and the subsequent pathologic specimens. RESULTS: One-third of the patients had bilateral pelvic masses; another third had large masses indistinguishable from the ovaries. Twelve (67%) had either ascites, peritoneal implants, matted bowel, adenopathy, pleural effusions, or some combination of these. Five (28%) had other metastatic disease. Primary tumors included colon adenocarcinoma (9), Burkitt's lymphoma (3), alveolar rhabdomyosarcoma (3), Wilms' tumor (1), neuroblastoma (1), and retinoblastoma (1). CONCLUSION: Although rare, secondary ovarian tumors should be considered in the differential diagnosis of children with ovarian masses. Bilateral ovarian masses or large masses indistinguishable from the ovaries, particularly in the presence of other metastatic foci, may help distinguish primary from secondary ovarian malignancies.


Subject(s)
Ovarian Neoplasms/secondary , Adenocarcinoma/pathology , Adolescent , Adrenal Gland Neoplasms/pathology , Burkitt Lymphoma/pathology , Child , Colonic Neoplasms/pathology , Diagnosis, Differential , Female , Humans , Kidney Neoplasms/pathology , Neuroblastoma/pathology , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology , Retinal Neoplasms/pathology , Retinoblastoma/pathology , Rhabdomyosarcoma, Alveolar/pathology , Statistics as Topic , Tomography, X-Ray Computed , Wilms Tumor/pathology
12.
Cancer Detect Prev ; 25(1): 48-54, 2001.
Article in English | MEDLINE | ID: mdl-11270421

ABSTRACT

We evaluated parameters of cell differentiation and proliferation to improve prognostication of ovarian adult granulosa cell tumors. Recurrent tumors (n = 10, REC group) and nonrecurrent tumors (n = 30, NED group) were compared in terms of cellular atypia, nuclear area, p53 overexpression, ploidy, DNA index, mitosis count, S-phase fraction, and nucleolar organizer region number and area per cell. Cellular atypia was significantly more frequent in REC than NED tumors (50% versus 13%; P = .03). Mean nuclear area was significantly larger in the REC than in the NED group (44 microm2 versus 36 microm2; P = .006). Mitotic count was significantly higher in REC than NED tumors (mean of 4.8 versus 1.7; P = .004). S-phase fraction and ploidy did not predict outcome: neither did nucleolar organizer region numbers and area per cell, or p53 overexpression. Cellular atypia and mitotic count may help in determining the prognosis of adult granulosa tumors of the ovary. The histochemical parameters evaluated did not provide additional information.


Subject(s)
Granulosa Cell Tumor/pathology , Neoplasm Recurrence, Local/pathology , Ovarian Neoplasms/pathology , Adult , Aneuploidy , Cell Differentiation , Cell Division , Cell Nucleus/ultrastructure , Female , Flow Cytometry , Granulosa Cell Tumor/metabolism , Granulosa Cell Tumor/ultrastructure , Humans , Mitosis , Nucleolus Organizer Region/ultrastructure , Prognosis , S Phase , Tumor Suppressor Protein p53/metabolism
13.
Obstet Gynecol ; 97(1): 101-8, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11152917

ABSTRACT

OBJECTIVE: To determine the effects of estrone sulfate alone or with different doses of medroxyprogesterone acetate on serum lipid and lipoprotein levels. METHODS: A multicenter, double-masked, randomized trial for 1 year involved 682 postmenopausal women, aged 53.8 +/- 0.2 years (mean +/- standard deviation) with intact uteri. Subjects received fixed daily doses of 0.625 mg of estrone sulfate and one of the following regimens: placebo; 2.5 mg daily of medroxyprogesterone acetate; 5 mg daily of medroxyprogesterone acetate; or 10 mg of medroxyprogesterone acetate for the first 12 days of each 28-day cycle. Fasting lipid and lipoprotein levels were measured at baseline and weeks 12, 16, 24, 30, 36, and 52 of treatment. Absolute mean changes from baseline were determined by paired t test, and treatment effects were determined by analysis of variance. RESULTS: Total cholesterol levels decreased significantly (P <.05) from baseline in all study groups; however, reduction was significantly greater (P <.001) in the 2.5-, 5-, and 10-mg groups (-13.3%, -15.2%, and -14.1%) than in the placebo group (-4.9%). Low-density lipoprotein cholesterol levels decreased significantly and equally in all groups (-10.1% to -12.3%). High-density lipoprotein cholesterol levels increased by 3.2% with unopposed estrogen (P <.05) and did not change from baseline with combined therapy. Triglyceride and very low-density lipoprotein cholesterol levels increased by 13.4% and 2.7%, respectively, in the placebo group, did not change in the 2.5-mg group, decreased by 10.2% and 2.0% and by 11.4% and 2.2% in the 5- and 10-mg groups, respectively (P <.05). CONCLUSION: Estrone sulfate at the daily dose of 0.625 mg alone or with medroxyprogesterone acetate significantly improved lipoprotein levels. Combined therapy with medroxyprogesterone acetate and estrone sulfate was associated with statistically significantly greater reduction in total cholesterol and statistically significantly less increase in triglyceride levels than unopposed estrone sulfate therapy.


Subject(s)
Estrone/analogs & derivatives , Estrone/pharmacology , Lipoproteins/blood , Medroxyprogesterone Acetate/pharmacology , Postmenopause/physiology , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Double-Blind Method , Drug Combinations , Estrone/administration & dosage , Female , Humans , Medroxyprogesterone Acetate/administration & dosage , Middle Aged , Triglycerides/blood
14.
Psychopharmacol Bull ; 35(3): 135-49, 2001.
Article in English | MEDLINE | ID: mdl-12397883

ABSTRACT

Premenstrual exacerbation of mood disorders has received little attention, despite the recent interest in premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). Differentiating between PMDD/PMS and other disorders, which worsen premenstrually, is a poorly understood diagnostic challenge. Controversy also focuses on a possible coexistence of PMDD and other mood disorders. This review discusses the differences between mood-disorder exacerbations and premenstrual disorders, evidence for premenstrual magnification of mood disorders, and possible mechanisms for these variations as well as clinical implications.


Subject(s)
Mood Disorders/psychology , Premenstrual Syndrome/psychology , Adolescent , Adult , Bipolar Disorder/complications , Bipolar Disorder/psychology , Depressive Disorder/complications , Depressive Disorder/psychology , Female , Humans , Mood Disorders/complications , Premenstrual Syndrome/complications
15.
Menopause ; 7(5): 318-26, 2000.
Article in English | MEDLINE | ID: mdl-10993031

ABSTRACT

OBJECTIVES: The purpose of this investigation was to evaluate the relative efficacy of the sublingual administration of micronized estradiol (E2), progesterone (P4), and testosterone (T) on bone mineral density and biochemical markers of bone metabolism. DESIGN: In this double-blind, prospective study, postmenopausal women were randomly assigned to one of four treatment groups: hysterectomized women were assigned to either 1) micronized E2 (0.5 mg) or 2) micronized E2 (0.5 mg) + micronized T (1.25 mg). Women with intact uteri were assigned to either 3) micronized E2 (0.5 mg) + micronized P4 (100 mg) or 4) micronized E2 (0.5 mg) + micronized P4 (100 mcg) + micronized T (1.25 mg). For the purpose of this study, the four treatment groups were combined into two groups for all comparisons. The E2 and E2+P4 groups were combined into the HRT alone group (n=30), and the E2+T and E2+P4+T groups were combined into the HRT + T group (n=27). Hormones were administered sublingually as a single tablet twice a day for 12 months. Bone mineral density was measured in the anterior-posterior lumbar spine and total left hip via dual energy x-ray absorptiometry. Bone metabolism was assessed via serum bone-specific alkaline phosphatase and urinary deoxypyridinoline and cross-linked N-telopeptide of type I collagen, both normalized to creatinine. Data were analyzed via a repeated measures analysis of variance and a Student's t test (alpha=0.05). RESULTS: The subjects were of similar age (54.0 +/- 0.8 years), height (64.0 +/- 0.3 in), weight (157.6 +/- 4.2 lb), and had similar baseline follicle-stimulating hormone (66.4 +/- 3.2 mIU/L), E2 (26.4 +/- 1.5 pg/ml), P4 (0.3 +/- 0.1 ng/ml), total T (19.0 +/- 1.5 ng/dL), and bioavailable T (3.7 +/- 0.3 ng/dL) levels. During therapy, serum levels increased (p < 0.05) for each hormone. Bone mineral density and bone markers at baseline were similar for each treatment group. Bone-specific alkaline phosphatase decreased (p < 0.05) by -14.3 +/- 4.1% in the HRT alone group and by -8.2 +/- 4.6% in the HRT + T group. Deoxypyridinoline levels decreased significantly in the HRT alone and HRT + T groups, - 14.4 +/- 6.8% and -26.9 +/- 7.6%, respectively. Significant reductions (p < 0.05) in cross-linked N-telopeptide of type I collagen were also observed in both groups, -24.4 +/- 6.5% and -39.5 +/- 8.6%, respectively. Bone mineral density in the lumbar spine increased (p < 0.05) by +2.2 +/- 0.5% the HRT alone group and by + 1.8 +/- 0.6% in the HRT + T group. Total hip bone mineral density was maintained in the HRT alone group (+0.4 +/- 0.4%) and increased (p < 0.05) in the HRT + T group (+ 1.8 +/- 0.5%). CONCLUSIONS: Sublingual micronized HRT favorably decreases serum and urine markers of bone metabolism, prevents bone loss, and results in a slight increase in spine and hip bone mineral density. Although the addition of testosterone to HRT for 1 year did not result in added benefit to the spine bone mineral density, it did result in a significant increase in hip bone mineral density. Longer duration of therapy may have further improved these outcomes.


Subject(s)
Bone Density/drug effects , Bone and Bones/metabolism , Estradiol/pharmacology , Hormone Replacement Therapy , Osteoporosis, Postmenopausal/prevention & control , Progesterone/pharmacology , Testosterone/pharmacology , Administration, Sublingual , Alkaline Phosphatase/blood , Amino Acids/urine , Collagen/urine , Double-Blind Method , Estradiol/administration & dosage , Estradiol/therapeutic use , Female , Humans , Middle Aged , Progesterone/administration & dosage , Progesterone/therapeutic use , Prospective Studies , Testosterone/administration & dosage , Testosterone/therapeutic use
16.
Anesth Analg ; 90(6): 1324-30, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10825314

ABSTRACT

UNLABELLED: Complex coagulopathies follow cardiopulmonary bypass (CPB) in children. However, objective laboratory data that can be acquired rapidly to guide their management are lacking. Because thromboelastography has proven useful in this regard, we evaluated the use of celite or tissue factor (TF) activation and heparinase modification of blood samples to allow rapid determination of thromboelastogram data in children younger than 2 yr undergoing CPB. Celite or TF activation shortened the initiation of clotting and, thus, the time required for the important thromboelastogram alpha and maximum amplitude values to begin evolving. Although thromboelastogram alpha and maximum amplitude values were increased with these activators, correlations persisted between platelet count or fibrinogen level and each of these values. The additional use of heparinase allowed thromboelastograms to be obtained during CPB with values not different from those obtained without heparinase after protamine administration. Therefore, celite- or TF-activated, heparinase-modified thromboelastograms begun during CPB allow objective data to be available by the conclusion of protamine administration to help restore hemostasis after CPB in children. Thromboelastography identified transient fibrinolysis during CPB in some children that resolved by the conclusion of protamine administration. Future investigations of the effectiveness of modified thromboelastography-guided coagulopathy management after CPB in children are needed. IMPLICATIONS: Thromboelastography is useful in assessing the coagulopathies that follow cardiopulmonary bypass in children. Modifying blood samples with celite or tissue factor and heparinase allows thromboelastography begun before the termination of cardiopulmonary bypass to become a rapid point-of-care monitor to provide objective data for guiding blood component therapy to manage these coagulopathies.


Subject(s)
Blood Coagulation Disorders/diagnosis , Cardiopulmonary Bypass , Postoperative Complications/diagnosis , Thrombelastography/methods , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Blood Coagulation Disorders/blood , Blood Coagulation Tests , Diatomaceous Earth , Female , Hemostatics , Heparin/adverse effects , Heparin/therapeutic use , Heparin Antagonists , Heparin Lyase , Humans , Infant , Infant, Newborn , Male , Postoperative Complications/blood , Protamines , Thromboplastin
17.
Ann Thorac Surg ; 68(5): 1698-703; discussion 1703-4, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10585045

ABSTRACT

BACKGROUND: Direct cavopulmonary connection using an extracardiac conduit has a number of theoretical advantages in the staged management of children with single ventricular congenital heart defects. With appropriate planning, completion Fontan using an extracardiac connection may be accomplished without the use of cardiopulmonary bypass. METHODS: From January 1995 to October 1997, 32 consecutive patients underwent completion Fontan using an extracardiac cavopulmonary connection. Twenty-one of these patients had completion Fontan without the use of cardiopulmonary bypass (No CPB group). Their postoperative outcome was retrospectively compared with a second group of 11 patients who underwent completion Fontan with an extracardiac conduit with the use of cardiopulmonary bypass. RESULTS: There was no operative or hospital mortality in either group. Early postoperative hemodynamics appear to be significantly improved in the No CPB group. Transfusion of cryoprecipitate and platelets was significantly less in the group without the use of cardiopulmonary bypass (p = 0.026, p < 0.001, respectively). Review of the most recent 12 patients also demonstrated a substantially shorter extubation time and intensive care unit stay. The length of hospital stay was significantly shorter (p = 0.036). CONCLUSIONS: Completion Fontan without the use of cardiopulmonary bypass results in improved immediate postoperative hemodynamics, and decreased use of blood and blood products. The most recent group appears to demonstrate a more rapid recovery time and shorter hospital stay (p = 0.036).


Subject(s)
Cardiopulmonary Bypass , Fontan Procedure/methods , Heart Defects, Congenital/surgery , Anastomosis, Surgical , Angiography , Blood Vessel Prosthesis Implantation , Child, Preschool , Female , Heart Defects, Congenital/diagnostic imaging , Heart Ventricles/abnormalities , Heart Ventricles/diagnostic imaging , Heart Ventricles/surgery , Humans , Hypoplastic Left Heart Syndrome/diagnostic imaging , Hypoplastic Left Heart Syndrome/surgery , Infant , Male , Postoperative Complications/diagnostic imaging
18.
Life Sci ; 65(21): 2215-22, 1999.
Article in English | MEDLINE | ID: mdl-10576593

ABSTRACT

A total of 61 human brain specimens were analyzed with both ELISA and Western Blot using the ALZ50 monoclonal antibody. The brain specimens included: Alzheimer's Disease (AD, n=31), AD/Down's (n=2), Normal (n=14), Parkinson's Disease (n=7), Huntington's chorea (n=2), Wernicke-Korsakov's Encephalopathy (n=3), and Motor Neuron Disease (n=2). The non-AD cases (n=28) had no detectable A68 by ELISA, and showed no A68 bands by Western blot. The AD cases (n=33), all were positive for A68 by the ELISA, but only 31 of 33 had visible A68 band by Western blot. Additionally, a method for solubilization of A68 is reported.


Subject(s)
Alzheimer Disease/metabolism , Antibodies, Monoclonal , Antigens/immunology , Brain/metabolism , Nerve Tissue Proteins/metabolism , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Humans , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/isolation & purification , tau Proteins
19.
J Womens Health Gend Based Med ; 8(7): 989-93, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10534302

ABSTRACT

We discuss specific problems in implementing research to evaluate exercise treatment for premenstrual syndrome (PMS). Modifications of lifestyle, such as implementing exercise regimens, frequently are recommended as treatment for PMS, but evidence supporting this treatment is largely anecdotal. Originally, we designed a study to examine the effects of physical exercise on the symptoms of PMS. Despite initial enthusiasm, the majority of participants dropped out before beginning the active intervention segment of the study. This unexpected attrition resulted in a review of methodology, including recruitment and study design, in an attempt to understand factors related to research on exercise-based treatments of PMS so future researchers would be cognizant of the obstacles inherent in such research. Such understanding will allow research to advance more efficiently by enabling investigators to avoid the pitfalls we identified.


Subject(s)
Premenstrual Syndrome , Exercise , Female , Humans , Life Style , Patient Dropouts , Patient Selection , Premenstrual Syndrome/prevention & control , Premenstrual Syndrome/rehabilitation , Research Design
20.
Bioorg Med Chem ; 7(6): 1131-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10428384

ABSTRACT

Replacement of the 3,4-dialkoxyphenyl substructure common to a number of PDE4 inhibitors with a 2-alkyl-7-methoxybenzofuran unit is described. This substitution can result in either enhancement or substantial reductions in PDE4 inhibitory activity depending on the system to which it is applied. An in vitro SAR study of a potent series of 4-(2-heteroaryl-ethyl)-benzoiurans 26 is also presented.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Benzofurans/chemistry , Enzyme Inhibitors/chemistry , Animals , Benzofurans/pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 4 , Endotoxemia/chemically induced , Enzyme Inhibitors/pharmacology , Male , Mice , Mice, Inbred BALB C , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...